Investigation Report on China Nifuratel Market, 2010-2019
Description
Gynecological inflammation is a disease that troubles contemporary women. According to WHO’s survery on the health conditions of women all over the world, the incidence of gynecological disease has reached over 65% and over 70% among women of childbearing age. The number of cases of urinary system infections has hit over 300 million around the world, which leads to the rapid expansion of gynecological drug market. The epidemiological study conducted by China also shows that the incidence of reproductive tract infection among urban married women has exceeded 40% in China and that many women suffer from different degrees of urinary system infection in their lifetime.
Nifuratel can effectively kill those bacteria, protozoa and molds that lead to vaginal infections without any acute or chronic side effects. Due to its pleiotropic effects, nifuratel can be used for all kinds of vaginitis caused by bacteria, trichomonas and molds infection. Nifuratel, a variety of broad-spectrum antimicrobial agents with two methods of application: oral and external application, was developed by Doppel Farmaceutici. S. r. l. with the trade name of Macmiror/ Macmiror. In 2001, SFDA approved nifuratel made by Doppel Farmaceutici. S. r. l. to be sold in China with such main species as sugarcoated tablets, vaginal tablets and vaginal suppositories under the trade names of Macmiror and Macmiror Complex. Nifuratel develops fast after entering China with annual sales rising from CNY 53.2 thousand in 2005 to CNY 38.03 million in 2014 and CAGR reaching 24.43% and some Chinese enterprises have also started to make generic drugs.
With the fast development of Chinese economy and the improvement of national health insurance system, many kinds of gynecological inflammation drugs, driven by new concepts of treatment, have become affordable to civilians. In general, the gynecological anti-infective market in sample hospitals is dominated by pharmaceutical preparations which operate quickly. On the other hand, Chinese patent medicine made by local enterprises fail to enter the market, instead, they are widely used in mother and child healthcare hospitals, medical institutions based in communities as well as the rural market.
Readers can get at least the following information through this report:
Gynecological inflammation is a disease that troubles contemporary women. According to WHO’s survery on the health conditions of women all over the world, the incidence of gynecological disease has reached over 65% and over 70% among women of childbearing age. The number of cases of urinary system infections has hit over 300 million around the world, which leads to the rapid expansion of gynecological drug market. The epidemiological study conducted by China also shows that the incidence of reproductive tract infection among urban married women has exceeded 40% in China and that many women suffer from different degrees of urinary system infection in their lifetime.
Nifuratel can effectively kill those bacteria, protozoa and molds that lead to vaginal infections without any acute or chronic side effects. Due to its pleiotropic effects, nifuratel can be used for all kinds of vaginitis caused by bacteria, trichomonas and molds infection. Nifuratel, a variety of broad-spectrum antimicrobial agents with two methods of application: oral and external application, was developed by Doppel Farmaceutici. S. r. l. with the trade name of Macmiror/ Macmiror. In 2001, SFDA approved nifuratel made by Doppel Farmaceutici. S. r. l. to be sold in China with such main species as sugarcoated tablets, vaginal tablets and vaginal suppositories under the trade names of Macmiror and Macmiror Complex. Nifuratel develops fast after entering China with annual sales rising from CNY 53.2 thousand in 2005 to CNY 38.03 million in 2014 and CAGR reaching 24.43% and some Chinese enterprises have also started to make generic drugs.
With the fast development of Chinese economy and the improvement of national health insurance system, many kinds of gynecological inflammation drugs, driven by new concepts of treatment, have become affordable to civilians. In general, the gynecological anti-infective market in sample hospitals is dominated by pharmaceutical preparations which operate quickly. On the other hand, Chinese patent medicine made by local enterprises fail to enter the market, instead, they are widely used in mother and child healthcare hospitals, medical institutions based in communities as well as the rural market.
Readers can get at least the following information through this report:
- market size of nifuratel in China
- major manufacturers of nifuratel in the Chinese market and their market share
- retail price of nifuratel in Chinese market
- market outlook of nifuratel in China
- manufacturers of gynecological drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF NIFURATEL
1.2 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF NIFURATEL IN CHINA, 2010-2015
2.1 Patent and Approval Status of Nifuratel in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF NIFURATEL IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF NIFURATEL IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF NIFURATEL IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF NIFURATEL IN CHINESE HOSPITALS IN 2014
6.1 Monsanto Italy S.p.A. (Trade Name: Macmiror)
6.2 Beijing Laneva Pharmaceutical Co., Ltd (Trade Name: Lang Yi Jun)
6.3 Lifecare (Trade Name: Kuaihe) (Trade Name: Kuaihe)
6.4 Doppel Farmaceutici (Italy) (Trade Name: Macmiror)
6.5 Yantai Luyin Pharmaceutical Co., Ltd (Trade Name: Pu Le)
7 MAJOR MANUFACTURERS OF NIFURATEL IN CHINESE MARKET, 2010-2014
7.1 Lifecare
7.2 Beijing Laneva Pharmaceutical Co., Ltd
7.3 Yantai Luyin Pharmaceutical Co., Ltd
7.4 Doppel Farmaceutici (Italy)
7.5 Monsanto Italy S.p.A.
8 MARKET OUTLOOK OF NIFURATEL IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
Table of Selected Contents
Chart Patent Status of Nifuratel in China
Chart Approval Status of Nifuratel in China
Chart Sales Status of Nifuratel in Chinese Market, 2010-2014
Chart Sales Value of Nifuratel in China, 2010-2014
Chart Sales Value of Nifuratel in Some Regions in China, 2010-2014
Chart Sales Volume of Nifuratel in China, 2010-2014
Chart Sales Volume of Nifuratel in Some Regions in China, 2010-2014
Chart Market Share of TOP5 Manufacturers of Nifuratel for Sales Value, 2010-2014
Chart Sales Value and Market Share of Nifuratel Made by Doppel Farmaceutici (Italy) in China, 2010-2014
Chart Sales Value and Market Share of Nifuratel Made by Beijing Laneva in China, 2010-2014
Chart Sales Value and Market Share of Nifuratel Made by Lifecare in China, 2010-2014
Chart Sales Value and Market Share of Nifuratel Made by Monsanto (IT) in China, 2010-2014
Chart Market Share of TOP5 Manufacturers of Nifuratel for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Nifuratel Tablets in China, 2010-2014
Chart Sales Value and Market Share of Nifuratel Capsules in China, 2010-2014
Chart Price of Nifuratel Made by Doppel Farmaceutici (Italy) in Some Chinese Cities in 2014
Chart Price of Nifuratel Made by Beijing Laneva Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Nifuratel Made by Lifecare in Some Chinese Cities in 2014
Chart Price of Nifuratel Made by Doppel Farmaceutici (Italy) in Some Chinese Cities in 2014
Chart Price of Nifuratel Made by Yantai Luyin Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
1.2 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF NIFURATEL IN CHINA, 2010-2015
2.1 Patent and Approval Status of Nifuratel in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF NIFURATEL IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF NIFURATEL IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF NIFURATEL IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF NIFURATEL IN CHINESE HOSPITALS IN 2014
6.1 Monsanto Italy S.p.A. (Trade Name: Macmiror)
6.2 Beijing Laneva Pharmaceutical Co., Ltd (Trade Name: Lang Yi Jun)
6.3 Lifecare (Trade Name: Kuaihe) (Trade Name: Kuaihe)
6.4 Doppel Farmaceutici (Italy) (Trade Name: Macmiror)
6.5 Yantai Luyin Pharmaceutical Co., Ltd (Trade Name: Pu Le)
7 MAJOR MANUFACTURERS OF NIFURATEL IN CHINESE MARKET, 2010-2014
7.1 Lifecare
7.2 Beijing Laneva Pharmaceutical Co., Ltd
7.3 Yantai Luyin Pharmaceutical Co., Ltd
7.4 Doppel Farmaceutici (Italy)
7.5 Monsanto Italy S.p.A.
8 MARKET OUTLOOK OF NIFURATEL IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
Table of Selected Contents
Chart Patent Status of Nifuratel in China
Chart Approval Status of Nifuratel in China
Chart Sales Status of Nifuratel in Chinese Market, 2010-2014
Chart Sales Value of Nifuratel in China, 2010-2014
Chart Sales Value of Nifuratel in Some Regions in China, 2010-2014
Chart Sales Volume of Nifuratel in China, 2010-2014
Chart Sales Volume of Nifuratel in Some Regions in China, 2010-2014
Chart Market Share of TOP5 Manufacturers of Nifuratel for Sales Value, 2010-2014
Chart Sales Value and Market Share of Nifuratel Made by Doppel Farmaceutici (Italy) in China, 2010-2014
Chart Sales Value and Market Share of Nifuratel Made by Beijing Laneva in China, 2010-2014
Chart Sales Value and Market Share of Nifuratel Made by Lifecare in China, 2010-2014
Chart Sales Value and Market Share of Nifuratel Made by Monsanto (IT) in China, 2010-2014
Chart Market Share of TOP5 Manufacturers of Nifuratel for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Nifuratel Tablets in China, 2010-2014
Chart Sales Value and Market Share of Nifuratel Capsules in China, 2010-2014
Chart Price of Nifuratel Made by Doppel Farmaceutici (Italy) in Some Chinese Cities in 2014
Chart Price of Nifuratel Made by Beijing Laneva Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Nifuratel Made by Lifecare in Some Chinese Cities in 2014
Chart Price of Nifuratel Made by Doppel Farmaceutici (Italy) in Some Chinese Cities in 2014
Chart Price of Nifuratel Made by Yantai Luyin Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
